Eucalyptus Health has raised $1.4B across 7 funding rounds, plus 1 undated round. The latest round valued Eucalyptus Health at $1.1B post-money, with Hims & Hers Health on the lead line.
Eucalyptus raised A$8 million in Series A funding, then $30 million in Series B and $60 million in Series C, reaching a $560 million valuation by April 2023. Hims & Hers Health then acquired the company in a deal worth up to $1.15 billion, completed in June 2026.
7 funding rounds, the latest highlighted.
Eucalyptus Health was founded in 2019, Australia.
No date is disclosed for this round.
A primary round — the company sells new shares to investors it selects. Led by Blackbird Ventures.
A primary round — the company sells new shares to investors it selects. Led by Blackbird Ventures.
A$8 million..
A primary round — the company sells new shares to investors it selects. $30M raised.
A primary round — the company sells new shares to investors it selects. $60M raised.
A$50 million..
A primary round — the company sells new shares to investors it selects. $1.1B raised, led by Hims & Hers Health.
No longer independent.
7 dated rounds, newest first.
Founders FundNo. Eucalyptus Health was acquired by Hims & Hers; its shares do not trade independently.
The last valuation is $1.1B (post-money, Feb 2026).
Lead investors for each round are in the funding timeline.
The closest digital health / telehealth peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
